New Dual-Target CAR T-Cell therapy aims to beat relapsed childhood cancers

NCT ID NCT05442515

Recruiting now Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 6 times

Summary

This study tests a new type of CAR T-cell therapy that targets two proteins, CD19 and CD22, on cancer cells. It is for children and young adults aged 3 to 39 with B-cell cancers like leukemia or lymphoma that have not been cured by standard treatments. Participants receive their own genetically modified immune cells after chemotherapy. The goal is to see if this therapy is safe and effective.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CD19/CD22 CAR T-cells
What this could lead to: If successful, this could offer a new treatment option for children and young adults with B-cell cancers that have come back after standard therapy.
What could go wrong: This is an early-phase trial, so the treatment may not work for everyone. There are risks of serious side effects like cytokine release syndrome and nervous system problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia B-cell acute lymphoblastic leukemia B-cell chronic lymphocytic leukemia B-cell neoplasm B-cell non-Hodgkin lymphoma blast phase chronic myelogenous leukemia, BCR-ABL1 positive Burkitt lymphoma diffuse large B-cell lymphoma high grade B-cell lymphoma indolent B-cell non-Hodgkin lymphoma Leukemia, B-Cell lymphoma lymphoma, non-Hodgkin, familial non-Hodgkin lymphoma Philadelphia Chromosome precursor B-cell acute lymphoblastic leukemia Precursor Cell Lymphoblastic Leukemia-Lymphoma Richter transformation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE LYMPHOBLASTIC LEUKEMIA ACUTE LYMPHOCYTIC LEUKEMIA ACUTE LYMPHOID LEUKEMIA B CELL LYMPHOMA B-ALL B-CELL LEUKEMIA B-NHL B-NON HODGKIN LYMPHOMA B-PRECURSOR ALL LEUKEMIA, LYMPHOCYTIC, B CELL LYMPHOMA, NON-HODGKIN

Contacts and locations

Locations

National Institutes of Health Clinical Center
RECRUITING

Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.